Victoza (liraglutide) causes digestive side effects in a significant number of users, with nausea affecting up to 20% of patients at the higher dose. Most of these effects are temporary and improve within weeks, but the drug also carries less common, more serious risks including pancreatitis, gallbladder problems, and kidney injury that are worth understanding before or during treatment.
Nausea, Vomiting, and Diarrhea
Digestive problems are by far the most common complaint. In clinical trials, 20% of patients on the 1.8 mg dose experienced nausea, compared to just 5% on placebo. Diarrhea affected about 12%, and vomiting hit 9%. These numbers drop slightly at the lower 1.2 mg dose (18% nausea, 10% diarrhea, 6% vomiting), which is one reason doctors start you on a lower dose and increase gradually. Decreased appetite, indigestion, and constipation round out the list of effects reported by more than 5% of users.
The reason for all this stomach trouble: Victoza mimics a gut hormone called GLP-1 that, among other things, slows down how quickly your stomach empties food into your intestines. After about three weeks of continuous treatment, this delay in gastric emptying becomes measurable. Your stomach holds food longer than it normally would, which triggers that persistent queasy feeling.
For most people, these symptoms are worst during the first few weeks and fade as the body adjusts. Nausea was the single biggest reason patients dropped out of clinical trials, but only 2.8% actually quit because of it. Another 1.5% stopped due to vomiting. The standard approach is to start at 0.6 mg daily for at least a week, then move to 1.2 mg, and eventually 1.8 mg if needed. Skipping this gradual ramp-up makes digestive side effects significantly worse.
Thyroid Tumor Warning
Victoza carries the FDA’s most serious warning, a boxed warning, about thyroid tumors. In animal studies, liraglutide caused tumors in thyroid C-cells (the cells that produce a hormone called calcitonin) in both rats and mice. These tumors were dose-dependent and more likely with longer treatment.
Whether this happens in humans is still unknown. The human relevance of what was observed in rodents hasn’t been determined. But because of this uncertainty, Victoza is completely off-limits if you or a close family member has ever had medullary thyroid carcinoma, or if you have a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Signs to be aware of include a lump or mass in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness that doesn’t go away.
Pancreatitis Risk
Acute pancreatitis, an inflammation of the pancreas, occurred at a notably higher rate in Victoza users during clinical trials. Across five trials involving more than 3,900 patients, seven cases of pancreatitis occurred in people taking Victoza versus just one case in patients on other diabetes medications. That works out to roughly a 4-to-1 imbalance after accounting for the number of people in each group.
Pancreatitis can be serious and occasionally life-threatening. The hallmark symptom is severe abdominal pain, often radiating through to your back, sometimes accompanied by nausea and vomiting. This is different from the garden-variety nausea that comes with starting Victoza. If you develop sudden, intense stomach pain that feels deeper and more severe than typical GI discomfort, that needs urgent medical attention.
Gallbladder and Biliary Problems
Victoza raises the risk of gallbladder complications. In the large LEADER cardiovascular outcomes trial, 3.1% of patients on liraglutide developed acute gallstone disease, compared to 1.9% on placebo. That translates to a 60% higher relative risk. The breakdown included gallbladder inflammation (cholecystitis) in about 1.1% of users, complicated gallstones in 1.1%, and biliary obstruction (a blocked bile duct) in 0.5%.
These numbers may sound small in absolute terms, but gallbladder problems often require surgery. Symptoms typically include pain in the upper right abdomen, especially after meals, sometimes with fever or yellowing of the skin. Rapid weight loss, which Victoza can promote, is itself a known risk factor for gallstones, so the two effects may compound each other.
Kidney Injury From Dehydration
Acute kidney injury has been reported in some Victoza users, and the connection is usually indirect. When nausea, vomiting, or diarrhea are severe enough to cause dehydration, your kidneys take the hit. This is especially relevant during the early weeks of treatment when GI symptoms tend to be at their worst, or if the dose is increased too quickly.
The practical concern here is that prolonged or unusually severe digestive symptoms aren’t just uncomfortable. They can become medically significant if fluid loss outpaces what you’re drinking. Staying hydrated matters more than usual when starting Victoza, and GI symptoms that are intense or lasting longer than expected are worth reporting to your prescriber rather than toughing out.
Increased Heart Rate
Victoza raises your resting heart rate by an average of about 2 to 3 beats per minute compared to placebo. A meta-analysis published in BMJ Open found the increase averaged 2.71 beats per minute. For most people, this is barely noticeable and not clinically meaningful. But if you already have a heart rhythm condition or take medications that affect heart rate, it’s something your doctor should factor in.
Low Blood Sugar With Certain Combinations
On its own, Victoza has a low risk of causing hypoglycemia (dangerously low blood sugar). The drug works in a glucose-dependent way, meaning it ramps up insulin production mainly when blood sugar is already elevated. But that safety net changes when Victoza is paired with other diabetes medications that independently lower blood sugar, particularly sulfonylureas or insulin. In those combinations, the risk of hypoglycemia goes up because the other drug keeps pushing blood sugar down regardless of where your levels are. If you’re on one of these combinations, your prescriber may need to lower the dose of the other medication.
Injection Site Reactions
Because Victoza is a daily injection, some people develop skin reactions at the injection site. These can include redness, itching, or a flat rash. Reports of allergic-type skin reactions like rashes and itching appear in the medical literature, though they’re uncommon. Rotating your injection site between your abdomen, thigh, and upper arm helps reduce irritation. A rash that developed in the first month of use has been described in case reports, suggesting the skin may react more during the adjustment period.